Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Transplantation Année : 2021

Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept

Résumé

Data about coronavirus disease 2019 (COVID-19) vaccine in the general population provided an excellent profile of immunogenicity strong antibody response following the second dose of mRNA-1273 or BNT162b2 vaccines, associated with a potent T-cell immune response.

Dates et versions

hal-03770797 , version 1 (06-09-2022)

Identifiants

Citer

Nathalie Chavarot, Amani Ouedrani, Olivier Marion, Marianne Leruez-Ville, Estelle Vilain, et al.. Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. Transplantation, 2021, 105 (9), pp.e94-e95. ⟨10.1097/TP.0000000000003784⟩. ⟨hal-03770797⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More